Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
Released Friday, 16th November 2018
Good episode? Give it some love!
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)
Friday, 16th November 2018
Good episode? Give it some love!
Rate Episode
Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population.
Show More
Rate
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Episode Tags
Do you host or manage this podcast?
Claim and edit this page to your liking.
,Claim and edit this page to your liking.
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us